Clinical Trial

Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).
Trial Details
NCT Number NCT07607561
Lead Sponsor SCAI Therapeutics
Conditions wetAMD, Age Related Macular Degeneration
Enrollment 50 participants
Start Date 2026-11-01
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-26